Search results for "analgesics"

showing 10 items of 260 documents

Synthesis and Pharmacological Activities of Novel 3-(Isoxazol-3-yl)-quinazolin-4(3H)-one Derivatives

1999

Several new 3-(isoxazol-3-yl)-quinazolin-4(3H)-one derivatives were synthesized and tested for their analgesic and antiinflammatory activities, as well as for their acute toxicity and ulcerogenic effect. A few compounds were as active as phenylbutazone in the writhing and acetic acid peritonitis tests. They had a very low ulcerogenic effect.

MaleStereochemistryAnalgesicAnti-Inflammatory AgentsPharmaceutical ScienceChemical synthesisRats Sprague-DawleyMiceStructure-Activity Relationshipchemistry.chemical_compoundAcetic acidDrug DiscoveryPhenylbutazonemedicineAnimalsStomach UlcerNuclear Magnetic Resonance BiomolecularAnalgesicsBehavior AnimalBicyclic moleculeAcute toxicityRatschemistryToxicityQuinazolinesLactammedicine.drugArchiv der Pharmazie
researchProduct

Postmortem distribution of dihydrocodeine and metabolites in a fatal case of dihydrocodeine intoxication.

1998

A report of a fatal dihydrocodeine ingestion under substitution therapy is given. Quantitation of dihydrocodeine, dihydromorphine, N-nordihydrocodeine, dihydrocodeine-6-, dihydromorphine-6- and dihydromorphine-3-glucuronide was performed simultaneously after solid-phase extraction prior to HPLC analysis, and the analytes were detected using their native fluorescence. Postmortem concentrations of blood samples from different sampling sites as well as from liver, kidney and cerebrum are reported. A hair sample was investigated to prove long-term use of the substitute drug. Site-to-site differences of the analytes from blood samples were very small. The partition behavior of the opioid glucuro…

AdultMaleMetaboliteDihydromorphineHematocritKidneyGas Chromatography-Mass SpectrometryPathology and Forensic Medicinechemistry.chemical_compoundFatal OutcomePharmacokineticsMedicineHumansActive metaboliteChromatography High Pressure LiquidBrain ChemistryMorphine DerivativesChromatographymedicine.diagnostic_testbusiness.industryCodeineCodeineDihydrocodeineAnalgesics OpioidchemistryLiverAnesthesiaDihydromorphinePostmortem ChangesToxicitybusinessLawBlood Chemical Analysismedicine.drugHairForensic science international
researchProduct

Perioperative nonspecific histamine release : a new classification by aetiological mechanisms and evaluation of their clinical relevance

1993

As a consequence of the performance of a randomized controlled clinical trial on perioperative histamine release and cardiovascular and respiratory disturbances, several types of increases in plasma histamine had to be distinguished instead of only two which existed at the beginning of the study: drug-induced allergic and pseudoallergic reactions. First of all, the new classification by aetiology (clinical epidemiology) was derived from a meta-analysis (secondary analysis) of the most recent literature. According to that histamine release in the perioperative period has several, different causes and is involved in several, different disease manifestations. A clear distinction (classificatio…

AdultMaleHistamine ReleaseDrug HypersensitivityIntraoperative Periodchemistry.chemical_compoundHumansMedicineAnesthesiaClinical significanceProspective StudiesAgedAnestheticsNeurosecretionbusiness.industryGeneral MedicinePerioperativeMiddle AgedPathophysiologyAnalgesics OpioidClinical trialAnesthesiology and Pain MedicinechemistryAnesthesiaEtiologyGastric acidFemalePremedicationNeuromuscular Blocking AgentsbusinessHistamineHistamineAnnales Françaises d'Anesthésie et de Réanimation
researchProduct

Does pain intensity predict a poor opioid response in cancer patients?

2011

Abstract Aim The aim of this study was to test the hypothesis that initial pain intensity is not a predictive factor of poor opioid response in advanced cancer patients, as suggested by a recent work. Methods A secondary analysis of one-hundred-sixty-seven patients referred for treatment of cancer-related pain was conducted. Pain intensity at admission was recorded and patients were divided in three categories of pain intensity: mild, moderate and severe. Patients were offered a treatment with opioid dose titration, according to department policy. Data regarding opioid doses and pain intensity were collected after dose titration was completed. Four levels of opioid response were considered:…

MaleCancer ResearchOpioid responseopioid response in cancer patientPainOpioidSettore MED/42 - Igiene Generale E ApplicataSecondary analysisNeoplasmsmedicineHumansProspective StudiesCancer painKarnofsky Performance StatusAdverse effectAgedPain Measurementpain intensityAnalgesicsAnalysis of VarianceAssessment tools; Cancer pain; Opioid response; Aged; Analgesics Opioid; Analysis of Variance; Female; Humans; Karnofsky Performance Status; Male; Middle Aged; Neoplasms; Pain; Pain Measurement; Prospective Studies; Treatment Outcome; Cancer Research; Oncologybusiness.industryCancerMiddle Agedmedicine.diseaseAdvanced cancerIntensity (physics)Predictive factorAnalgesics OpioidAssessment toolsTreatment OutcomeOncologyOpioidAnesthesiapain intensity; opioid response in cancer patients; trial clinicoFemaletrial clinicoCancer painbusinessmedicine.drugEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Low doses of transdermal fentanyl in opioid-naive patients with cancer pain.

2010

The aim of this study was to evaluate the effect and tolerability of low doses of transdermal (TD) fentanyl patches in opioid-naive patients with cancer pain.This was a nonrandomized, open-label, uncontrolled study in fifty consecutive opioid-naive patients with advanced cancer and moderate pain. TD fentanyl was initiated at a dose of 12 µg/h. Doses were then adjusted according to the clinical response. Pain intensity, opioid-related adverse effects, TD fentanyl doses, and quality of life were monitored over 4 weeks. The time to dose stabilization and indexes of dose escalation were also calculated.Thirty-one patients completed all 4 weeks of the study. Pain control was achieved within a me…

MaleTransdermal patchCancer pain; Opioids; Trandermal fentanyl; Aged; Analgesia; Analgesics Opioid; Dose-Response Relationship Drug; Female; Fentanyl; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasms; Pain; Palliative Care; Transdermal Patch; Medicine (all)medicine.medical_treatmentPainTransdermal PatchOpioidFentanylDose-Response RelationshipNeoplasmsmedicineHumansCancer painAdverse effectNeoadjuvant therapyTransdermalAgedAnalgesicsDose-Response Relationship Drugbusiness.industryMedicine (all)Palliative CareGeneral MedicineMiddle AgedNeoadjuvant TherapyOpioidsClinical trialAnalgesics OpioidFentanylTolerabilityTrandermal fentanylAnesthesiaFemaleDrugAnalgesiaCancer painbusinessmedicine.drugCurrent medical research and opinion
researchProduct

The gamma(2)-MSH peptide mediates a central analgesic effect via a GABA-ergic mechanism that is independent from activation of melanocortin receptors.

2001

Using the latency for tail-flick after thermal stimulation we have assessed the effects of alpha-, gamma(1)- and gamma(2)-MSH on nociceptive threshold in the mice. Intracisternal injections of gamma(2)-MSH induced a distinct analgesia, while gamma(1)-MSH in the same doses gave only a minor analgesia. Intracisternal alpha-MSH instead gave a short-term hyperalgesia. The effect of gamma(2)-MSH was not blocked by any of the MC(4)/MC(3)receptor antagonist HS014, naloxone or by the prior intracisternal administrations of gamma(1)-MSH. However, the gamma(2)-MSH analgesic response was completely attenuated by treating animals with the GABA(A)antagonist bicuculline. The gamma(2)-MSH analgesic effect…

MaleNarcotic Antagonists(+)-NaloxonePharmacologyGABA Antagonistschemistry.chemical_compoundMiceEndocrinologyDrug Interactionsgamma-Aminobutyric AcidAnalgesicsMice Inbred BALB Cintegumentary systemMuscimolNaloxoneReceptors MelanocortinNociceptorsGeneral MedicineReceptor antagonistNeurologyHyperalgesiamedicine.symptomhormones hormone substitutes and hormone antagonistsmedicine.drugPain ThresholdTailendocrine systemmedicine.medical_specialtyanimal structuresmedicine.drug_classCatalepsyBicucullinePeptides CyclicCellular and Molecular Neurosciencegamma-MSHMelanocortin receptorInternal medicinemedicineAnimalsGABA ModulatorsGABA AgonistsCatalepsyDiazepamEthanolEndocrine and Autonomic SystemsAntagonistCentral Nervous System DepressantsBicucullinemedicine.diseaseEndocrinologyMuscimolchemistryReceptors Corticotropinalpha-MSHNeuropeptides
researchProduct

The anti-inflammatory and antinociceptive effects of NF-κB inhibitory guanidine derivative ME10092

2010

The guanidine compound ME10092 (1-(3,4-dimethoxy-2-chlorobenzylideneamino)-guanidine) is known to possess anti-radical and anti-ischemic activity but its molecular targets have not been identified. This study investigated whether ME10092 regulates the nuclear factor kappa B (NF-kappaB)-mediated signal transduction in vivo. The effect of ME10092 treatment (1-100 pmol/mouse) on nuclear translocation of NF-kappaB, activation of expression of inflammatory mediators and production of nitric oxide were measured in the lipopolysaccharide (LPS)-induced brain inflammation model in mice in vivo. The antinociceptive activity of ME10092 was tested in the formalin-induced paw licking test. ME10092 dose-…

LipopolysaccharidesMaleNecrosisTranscription GeneticLipopolysaccharidemedicine.drug_classInterleukin-1betaImmunologyAdministration OralNitric Oxide Synthase Type IIInflammationPharmacologyNitric OxideGuanidinesAnti-inflammatoryNitric oxideMicechemistry.chemical_compoundIn vivoFormaldehydemedicineAnimalsImmunology and AllergyPain MeasurementPharmacologyAnalgesicsMice Inbred ICRbiologyTumor Necrosis Factor-alphaAnti-Inflammatory Agents Non-SteroidalNF-kappa BNitric oxide synthasechemistryCyclooxygenase 2Immunologybiology.proteinEncephalitisInflammation Mediatorsmedicine.symptomLickingSignal TransductionInternational Immunopharmacology
researchProduct

Opioid analgetics retention–pharmacologic activity models using biopartitioning micellar chromatography

2002

Opioids are drugs used in medicine for pain control. In this paper, retention-pharmacokinetics and retention-pharmacodynamics relationships of opioids are proposed and statistically validated. These models are based on the compound retention in the biopartitioning micellar chromatography system (BMC), a new methodology which has successfully been used to develop QRAR models for many other families of compounds. The obtained results are compared to the traditional QSAR models using lipophilicity data. The adequacy of QRAR models is due to the fact that the characteristics of the compounds such as the hydrophobicity, electronic charge and steric effects determine both their retention in BMC a…

Quantitative structure–activity relationshipChromatographyChemistryClinical BiochemistryAnalgesicCell BiologyGeneral MedicinePharmacologyBiochemistryAnalytical ChemistryAnalgesics OpioidStructure-Activity RelationshipModels ChemicalOpioidPain controlPharmacokineticsLipophilicitymedicineOpioid analgesicsChromatography Micellar Electrokinetic Capillarymedicine.drugJournal of Chromatography B
researchProduct

Development of a new multi-analyte assay for the simultaneous detection of opioids in serum and other body fluids using liquid chromatography-tandem …

2015

Abstract A liquid chromatography–tandem mass spectrometry method using electrospray ionization in positive ionization mode was developed for the simultaneous detection of multiple opioid-type drugs in plasma. The presented assay allows the quantitative determination of alfentanil, buprenorphine, codeine, desomorphine, dextromethorphan, dextrorphan, dihydrocodeine, dihydromorphine, ethylmorphine, fentanyl, hydrocodone, hydromorphone, methadone, morphine, naloxone, naltrexone, oxycodone, oxymorphone, pentazocine, pethidine, pholcodine, piritramide, remifentanil, sufentanil, and tramadol as well as the metabolites 6-monoacetylmorphine, bisnortilidine, morphine-3-glucuronide, morphine-6-glucuro…

ChromatographyChemistryClinical BiochemistryCodeineReproducibility of ResultsCell BiologyGeneral MedicineEthylmorphineBiochemistryDihydrocodeineAnalytical ChemistryTriple quadrupole mass spectrometerBody FluidsAnalgesics Opioidchemistry.chemical_compoundLiquid chromatography–mass spectrometryLimit of DetectionTandem Mass SpectrometryIntensive caremedicineMorphineHumansNorbuprenorphinemedicine.drugChromatography LiquidJournal of chromatography. B, Analytical technologies in the biomedical and life sciences
researchProduct

Opioid Plasma Concentrations during a Switch from Transdermal Fentanyl to Methadone

2007

Opioid switching is often used to improve the opioid response in patients with cancer experiencing poor analgesia or adverse effects. When switching between drugs with delayed effect because of pharmacokinetics or type of delivery, concerns exist about the correct timing of introducing the second drug after stopping the previous one. The aim of this study was to assess plasmatic changes of fentanyl and methadone underlying the clinical events occurring during opioid switching. Eighteen patients with cancer receiving transdermal fentanyl with uncontrolled pain and/or moderate to severe opioid adverse effects, were switched to oral methadone using an initial fixed ratio of 1:20. Fentanyl patc…

AdultMaleTime FactorsPalliative careAdministration Cutaneousmethadone.Drug Administration ScheduleFentanylPharmacokineticsNeoplasmsHumansMedicineAdverse effectGeneral NursingAgedPain MeasurementTransdermalbusiness.industrywitchingPalliative CareOpioid plasma concentrationGeneral MedicineMiddle Agedtransdermal fentanylPain IntractableAnalgesics OpioidFentanylTreatment OutcomeAnesthesiology and Pain MedicineOpioidBasal (medicine)AnesthesiaFemalebusinessMethadonemedicine.drugMethadoneJournal of Palliative Medicine
researchProduct